Polaryx Therapeutics, Inc. Common Stock
PLYXHealthcare|Biotechnology|US
$1.80
+0.06 (+3.45%)
DCF Value
$0.10
Tangible Book / Share
$0.23
Cash / Share
$0.24
Financials
Financial Snapshot
Market Cap
$89.7M
Enterprise Value
$78.2M
Revenue (TTM)
$0.00
Net Income (TTM)
-$6.8M
Cash & Investments
$11.5M
Net Cash
$11.5M
Free Cash Flow (TTM)
-$5.8M
Operating CF (TTM)
-$5.8M
Debt/Equity
0.00
Cash Runway & Burn Rate
Cash on Hand
$11.5M
Quarterly Burn
$1.5M
Monthly Burn
$484.1K
Est. Runway
~7.9 quarters
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Cash & Investments | $2.0K | $4.6M | $5.1M | $11.5M | |
| Operating Cash Flow | -$173.0K | -$2.6M | -$3.9M | -$5.8M | |
| Free Cash Flow | -$173.0K | -$2.6M | -$3.9M | -$5.8M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $128.0K | $7.2M | $4.5M | $14.0M |
R&D Spending
R&D (TTM)
$2.5M
R&D Intensity
—
R&D Growth vs Prior
-60.5%
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | $2.8M | $2.8M | $6.3M | $2.5M | |
| SG&A | $1.0M | $1.5M | $1.6M | $2.8M |
Income Statement
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 | |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D | $2.8M | $2.8M | $6.3M | $2.5M | |
| SG&A | $1.0M | $1.5M | $1.6M | $2.8M | |
| Operating Income | -$3.8M | -$4.4M | -$7.8M | -$5.2M | |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 | |
| Pretax Income | -$3.8M | -$30.4M | -$9.0M | -$6.8M | |
| Net Income | -$3.8M | -$30.4M | -$9.0M | -$6.8M | |
| EPS (Diluted) | -0.02 | -0.16 | -0.19 | -0.12 | |
| EBITDA | -$3.8M | -$30.4M | -$9.0M | -$6.8M | |
| Shares Out. (M) | 189.37 | 189.37 | 47.34 | 48.28 |
Balance Sheet
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Cash & Equivalents | $2.0K | $4.6M | $5.1M | $11.5M | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $2.3M | $5.0M | $5.2M | $11.8M | |
| Total Assets | $2.3M | $5.0M | $5.4M | $11.8M | |
| Total Current Liabilities | $1.0M | $289.0K | $605.0K | $873.0K | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $1.0M | $289.0K | $855.0K | $873.0K | |
| Stockholders' Equity | $1.3M | $4.7M | $4.6M | $10.9M | |
| Retained Earnings | -$60.3M | -$90.7M | -$99.6M | -$103.6M |
Cash Flow Statement
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Operating Cash Flow | -$173.0K | -$2.6M | -$3.9M | -$5.8M | |
| Capital Expenditure | $0.00 | $0.00 | $0.00 | $0.00 | |
| Free Cash Flow | -$173.0K | -$2.6M | -$3.9M | -$5.8M | |
| Investing Cash Flow | $0.00 | $0.00 | $0.00 | $0.00 | |
| Financing Cash Flow | $128.0K | $7.2M | $4.5M | $14.0M | |
| Issuance of Stock | $0.00 | $7.3M | $4.5M | $4.4M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $128.0K | -$128.0K | $0.00 | $0.00 | |
| Stock Based Comp. | $3.2M | $2.4M | $0.00 | $575.0K | |
| Net Change in Cash | -$45.0K | $4.6M | $522.0K | $8.2M |
Dilution Tracker
Shares Outstanding
50M
5-Year Share Growth
-75.0%
Stock Issuance (TTM)
$4.4M
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Shares Out. (M) | 189.37 | 189.37 | 47.34 | 48.28 | |
| Change vs Prior % | — | 0.0% | -75.0% | 2.0% | |
| Stock Issuance | $0.00 | $7.3M | $4.5M | $4.4M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $3.2M | $2.4M | $0.00 | $575.0K |
Margins & Profitability
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| ROE % | -295.9% | -644.2% | -196.8% | -117.6% | |
| ROA % | -163.2% | -607.0% | -165.8% | -58.0% | |
| ROIC % | -269.1% | -92.4% | -162.4% | -47.7% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -15.1% | -79.7% | |
| Net Income | 0.0% | -703.3% | 70.4% | |
| EPS (Diluted) | 0.0% | -700.0% | -18.8% | |
| Operating Cash Flow | 0.0% | -1387.3% | -53.3% | |
| Free Cash Flow | 0.0% | -1387.3% | -53.3% | |
| R&D Expense | 0.0% | 1.4% | 122.9% | |
| SG&A Expense | 0.0% | 52.6% | 0.9% | |
| Total Assets | 0.0% | 116.0% | 8.4% | |
| Book Value / Share | 0.0% | 269.0% | 287.5% | |
| Debt | 0.0% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | -75.0% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B7.94
10Y Low / Med / High362.98 / 1406.63 / 5190.32
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
DCF Value
$0.10
Tangible Book / Share
$0.23
Net Current Assets / Share
$0.22
Graham Net-Net
$0.22
Cash / Share
$0.24
| Metric | Trend | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| P/E Ratio | -1750.00 | -218.75 | -184.21 | -14.79 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | 5190.32 | 1406.63 | 362.98 | 7.94 | |
| EV/EBITDA | -1753.95 | -218.19 | -183.85 | -11.41 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
48.59
Safe
Piotroski F-Score
3
Weak
Forward Estimates (consensus)
| Metric | FY2026 | FY2027 | FY2028 |
|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.8M | -$13.5M | -$18.0M |
| EPS | $-0.19 | $-0.29 | $-0.36 |
| # Analysts (EPS) | 3 | 3 | 3 |